Decoding the Tumor Microenvironment: Advanced Proteomics for Biomarker Discovery & Immunotherapy Advancements

Join us for this live webinar, co-organized with our partner RayBiotech, to explore how advancements in multiplex proteomic analysis tools can unlock critical insights into the tumor microenvironment and guide the development of more effective immunotherapy strategies.

What is this webinar about?

Decades of intensive research into the tumor microenvironment (TME) have revealed its crucial role in modulating therapeutic efficacy and resistance through dynamic cellular crosstalk. Tumor stromal cells secrete diverse signaling molecules that drive oncogenic pathways, immune evasion, and epigenetic reprogramming. These complex signaling networks present both challenges and opportunities for therapeutic intervention.

This webinar will explore how recent advances in affinity proteomic technology have enabled systematic interrogation of TME-derived factors through high-throughput protein profiling. Antibody arrays which could previously capture several hundred proteins per array have expanded their capacity to 8000+ proteins while maintaining their ng to pg/ml sensitivity. 

Raybiotech expert will discuss how these-density array platforms have emerged as powerful tools for mapping tumor-immune interactions, identifying predictive biomarkers, covering drug resistance mechanisms, guiding the development of more effective immunotherapy strategies.

Why should you attend?

Join us for this webinar to explore how advanced multiplex proteomic analysis tools from our partner RayBiotech can unlock critical insights into the tumor microenvironment, including:

• Mechanisms of resistance to targeted therapies
• Identification of key drug targets for combination treatments
• TME signatures that predict patient responses to targeted therapies
• The role of blood-based biomarkers in non-invasive immune monitoring and identifying responders to immune checkpoint inhibition (ICI)

Who should attend?

Researchers and scientists working in oncology, immunotherapy, and biomarker discovery should attend to learn :

• How high-density antibody arrays can enhance your understanding of tumor-immune interactions and improve therapeutic strategies.
• Technological improvements made by Raybiotech on antibody arrays in terms of capacity and sensitivity.

Your webinar presenters

Got Questions? We're Here to Help!

Reach out our team and get the answers you need